The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale.
Atrial Fibrillation
/ diagnosis
Drug Costs
Drug Utilization
Egypt
/ epidemiology
Fibrinolytic Agents
/ adverse effects
Humans
Middle East
/ epidemiology
Practice Patterns, Physicians'
Prospective Studies
Registries
Research Design
Risk Assessment
Risk Factors
Stroke
/ diagnosis
Thromboembolism
/ diagnosis
Time Factors
Treatment Outcome
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
25
6
2020
medline:
8
6
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Atrial fibrillation is the most common cardiac arrhythmia, affecting 33.5 million patients globally. It is associated with increased morbidity, leading to significant clinical and economic burden. There exist only limited data in the Middle Eastern region from the existing registries. The goal of the FLOW-AF (atrial FibriLlatiOn real World management registry in the Middle East and Africa) registry is to evaluate the characteristics, treatment patterns, and clinical and economic outcomes associated with anticoagulation among patients newly diagnosed with nonvalvular atrial fibrillation in Egypt, Lebanon, the Kingdom of Saudi Arabia, and the United Arab Emirates. This study will be a multicountry, multicenter, prospective observational registry aiming to enroll 1446 newly diagnosed nonvalvular atrial fibrillation patients at more than 20 sites across the four countries. During the recruitment period, patients will be included if they were newly diagnosed with nonvalvular atrial fibrillation and had initiated treatment for the prevention of stroke/systemic embolism. Patient data will be assessed prospectively at 6 and 12 months from their enrollment date. Demographics, clinical characteristics, antithrombotic treatments received, clinical outcomes, adverse events, healthcare resource utilization, and direct costs associated with management of nonvalvular atrial fibrillation will be collected and analyzed overall, by country, and by groups created based on treatment, demographics, and clinical characteristics, medical history and risk factors. The FLOW-AF registry will provide information on the uptake of oral anticoagulants, treatment patterns, clinical outcomes, and healthcare utilization and costs among newly diagnosed nonvalvular atrial fibrillation patients in the Middle Eastern region.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial fibrillation is the most common cardiac arrhythmia, affecting 33.5 million patients globally. It is associated with increased morbidity, leading to significant clinical and economic burden. There exist only limited data in the Middle Eastern region from the existing registries. The goal of the FLOW-AF (atrial FibriLlatiOn real World management registry in the Middle East and Africa) registry is to evaluate the characteristics, treatment patterns, and clinical and economic outcomes associated with anticoagulation among patients newly diagnosed with nonvalvular atrial fibrillation in Egypt, Lebanon, the Kingdom of Saudi Arabia, and the United Arab Emirates.
METHODS
METHODS
This study will be a multicountry, multicenter, prospective observational registry aiming to enroll 1446 newly diagnosed nonvalvular atrial fibrillation patients at more than 20 sites across the four countries. During the recruitment period, patients will be included if they were newly diagnosed with nonvalvular atrial fibrillation and had initiated treatment for the prevention of stroke/systemic embolism. Patient data will be assessed prospectively at 6 and 12 months from their enrollment date. Demographics, clinical characteristics, antithrombotic treatments received, clinical outcomes, adverse events, healthcare resource utilization, and direct costs associated with management of nonvalvular atrial fibrillation will be collected and analyzed overall, by country, and by groups created based on treatment, demographics, and clinical characteristics, medical history and risk factors.
CONCLUSION
CONCLUSIONS
The FLOW-AF registry will provide information on the uptake of oral anticoagulants, treatment patterns, clinical outcomes, and healthcare utilization and costs among newly diagnosed nonvalvular atrial fibrillation patients in the Middle Eastern region.
Identifiants
pubmed: 32576751
doi: 10.2459/JCM.0000000000001007
pii: 01244665-202009000-00014
doi:
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
704-710Références
Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36:1115–1119.
Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013; 34:1061–1067.
Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004; 25:1734–1740.
Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27:1765–1769.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of nonvitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J 2017; 38:2137–2149.
Boriani G, Cimaglia P, Fantecchi E, et al. Nonvalvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. J Cardiovasc Med (Hagerstown) 2015; 16:491–496.
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129:837–847.
Johnston KM, Osenenko KM, Qatami L, et al. Healthcare resource utilization and costs in individuals with atrial fibrillation in United Arab Emirates and Kingdom of Saudi Arabia: a retrospective cohort study. Int J Integr Med 2015; 4:17–25.
El Kadri M, Bazargani N, Farghaly M, et al. Profiling clinical characteristics and treatment patterns among nonvalvular atrial fibrillation patients: a real-world analysis in Dubai, United Arab Emirates. Open Med J 2019; 6:33–41.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955–962.
Hersi A, Al Fagih A, Almusaad A, et al. Clinical practice guideline on antithrombotic treatment of patients with nonvalvular atrial fibrillation: The Saudi Center for EBHC Clinical Practice Guideline. The Saudi Arabia Ministry of Health website. Available at: https://www.moh.gov.sa/en/Search/Pages/Default.aspx?k=Clinical%20practice%20guideline%20on%20antithrombotic%20treatment%20of%20patients%20with%20nonvalvular%20atrial%20fibrillation. (Accessed 15 January 2019)
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37:2893–2862.
Andrade JG, Verma A, Mitchell LB, et al. CCS Atrial Fibrillation Guidelines Committee. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2018; 34:1371–1392.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Heart Rhythm 2019; 16:e66–e93.
Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331–339.
Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159:348–353.
ROCKET AF Study Investigators. Rivaroxaban — once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340.e1–347.e1.
Ezekowitz MD, Connolly SJ, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157:805.e1–810.e2.
Ahmed AM, Hersi A, Mashhoud W, et al. Cardiovascular risk factors burden in Saudi Arabia: the Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc 2017; 29:235–243.
Hersi A, Abdul-Moneim M, Almous’ad A, Al-Samadi F, AlFagih A, Sweidan R. Saudi Atrial Fibrillation Survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation. Angiology 2015; 66:244–248.
Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes 2011; 4:477–482.
Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163:13.e1–19. e1.
Mazurek M, Huisman MV, Rothman KJ, et al. GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost 2017; 117:2376–2388.
Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011; 162:606.e1–612.e1.
Apenteng PN, Murray ET, Holder R, Hobbs FR, Fitzmaurice DA. UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord 2013; 13:31.
Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. EP Europace 2009; 11:423–434.
Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. EP Europace 2013; 16:308–319.
Hersi AS, Alhebaishi YS, Hamoui O, et al. Practical perspectives on the use of nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: a view from the Middle East and North Africa. J Saudi Heart Assoc 2018; 30:122–139.
Heidenreich PA, Fonarow GC. Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. Am Heart J 2006; 152:935–939.
Granger CB, Gersh BJ. Clinical trials and registries in cardiovascular disease: competitive or complementary? 2010; 31:520–521.